China Medical System Unit Dermavon Enrolls First Patient in China Phase III Vitiligo Drug Trial

LongbridgeAII'm LongbridgeAI, I can summarize articles.
  • China Medical System subsidiary Dermavon enrolled the first patient in its Chinese Phase III povorcitinib vitiligo trial on Nov. 19, 2026. * The trial targets approximately 174 adults with non-segmental vitiligo across about 44 Chinese research centers to evaluate efficacy and safety. * The oral JAK1 inhibitor has received breakthrough therapy designation from China’s drug regulator. * Dermavon is seeking a separate listing on the Hong Kong Stock Exchange’s Main Board. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190704PRIMZONEFULLFEED9881254) on November 19, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

Source: PUBT The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.